Praxis Precision Medicines达到次要终点50%应答率 30毫克剂量组癫痫发作减少更显著

美股速递
Jun 02

Praxis Precision Medicines, Inc. 宣布其临床试验达到了关键的次要终点,即50%的应答率。数据显示,在降低癫痫发作频率方面,30毫克剂量组展现出了更为显著的效果。这一发现突显了该剂量在疗效上的优势,为后续的临床开发提供了重要依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10